Halozyme Therapeutics (HALO) news

Payward-Saldo deal seen closing in 2027

The anticipated merger between Payward and Saldo, two prominent players in the digital payments sector, is expected to finalize in 2027, according to recent regulatory filings and internal communications from both companies. The deal, which has been under review by antitrust authorities since early…

Halozyme Therapeutics, Inc.: TD Cowen raises target price to $130 from $105

TD Cowen has raised its price target for Halozyme Therapeutics, Inc. (HALO) to $130 from $105, reflecting positive outlook on HALO . HALO, which develops and commercializes drug-device combination products using advanced auto-injector technology, has seen its stock price rise in recent trading…

Havoc awarded SBIR phase III contract by Army Applications Laboratory for multi-domain mission collaborative autonomy

ActiveOps - Expects double digit adj EBITDA growth and increased PBT for H1 FY27

ActiveOps PLC (LON:AO), a global provider of AI-powered decision intelligence solutions for service operations, has indicated expectations of double-digit adjusted EBITDA growth and an increase in pre-tax profit (PBT) for the first half of fiscal year 2027 (H1 FY27). The company has not yet…

Argenx SE shares up 4.7%

Argenx SE (NASDAQ: ARGX) shares rose 4.7% on October 9, 2026, following continued momentum in the biotechnology sector and positive investor sentiment surrounding the company’s commercial performance. The stock is currently trading at $818.63, with a 52-week range of $661.85 to $1,072.75. The…